Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Shares Outstanding (Weighted Average) (2018 - 2026)

10x Genomics' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $124.7 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 3.57% to $124.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $124.7 million, a 3.57% increase, with the full-year FY2025 number at $124.7 million, up 3.57% from a year prior.
  • Shares Outstanding (Weighted Average) hit $124.7 million in Q4 2025 for 10x Genomics, down from $125.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for TXG hit a ceiling of $125.5 million in Q3 2025 and a floor of $108.7 million in Q1 2021.
  • Historically, Shares Outstanding (Weighted Average) has averaged $116.7 million across 5 years, with a median of $116.4 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 12.27% in 2021 and later increased 2.26% in 2023.
  • Tracing TXG's Shares Outstanding (Weighted Average) over 5 years: stood at $110.3 million in 2021, then grew by 3.18% to $113.9 million in 2022, then grew by 2.9% to $117.2 million in 2023, then increased by 2.81% to $120.5 million in 2024, then rose by 3.57% to $124.7 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TXG at $124.7 million in Q4 2025, $125.5 million in Q3 2025, and $123.2 million in Q2 2025.